Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: Work still in progress

Malignant mesothelioma (MM) is a rare and aggressive neoplasm, usually associated with a poor prognosis (5 years survival rate <10%). For unresectable disease, platinum and pemetrexed chemotherapy has been the only standard of care in first line for more than two decades, while no standard treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Perrino, Matteo, De Vincenzo, Fabio, Cordua, Nadia, Borea, Federica, Aliprandi, Marta, Santoro, Armando, Zucali, Paolo Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911663/
https://www.ncbi.nlm.nih.gov/pubmed/36776840
http://dx.doi.org/10.3389/fimmu.2023.1121557

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911663/
https://www.ncbi.nlm.nih.gov/pubmed/36776840
http://dx.doi.org/10.3389/fimmu.2023.1121557

Ejemplares similares